RIVAROXABAN HAS DEMONSTRATED AN ADVANTAGE OVER ACETYLSALICYLIC ACID IN PREVENTING THE RECURRENCE OF VENOUS THROMBOEMBOLIC EVENTS IN THE EINSTEIN CHOICE STUDY
Press Release of Bayer AG
Saved in:
| Main Author: | . Editorial |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2017-05-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Online Access: | https://www.rpcardio.online/jour/article/view/1458 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
THE ADVANCED TACTICS OF THE MANAGEMENT OF PATIENTS WITH VENOUS THROMBOEMBOLISM: THE ROLE OF RIVAROXABAN AT VARIOUS STAGES OF TREATMENT
by: S. R. Gilyarevskiy
Published: (2016-06-01) -
Plasma levels of direct Xa inhibitors apixaban and rivaroxaban in patients with venous thromboembolism in clinical practice
by: I. Paskaleva, et al.
Published: (2025-05-01) -
RIVAROXABAN IN THE PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ATRIAL FIBRILLATION
by: M. Yu. Gilyarov
Published: (2015-12-01) -
Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events
by: O. V. Shatalova
Published: (2015-12-01) -
Osteoporosis and venous thromboembolism
by: Irina Aleksandrovna Baranova, et al.
Published: (2011-02-01)